文献速递肝病

MAFLD考量应纳入全球丙型肝炎消除工作:国际视角

MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.
PubMed 文献 · Aliment Pharmacol Ther · 2021-03-22

本文从国际视角指出,世界卫生组织(WHO)计划2030年消除丙型肝炎(HCV),但代谢相关脂肪性肝病(MAFLD)患病率显著上升可能抵消直接抗病毒药物(DAA)对终末期肝病和肝细胞癌(HCC)的获益。国际专家建议对获得持续病毒学应答(SVR)的HCV患者采取整体、多学科管理,重视MAFLD的忽略影响。

要点

  • HCV消除目标需兼顾MAFLD上升对肝病进展的抵消作用
  • 对DAA治疗后获SVR者应纳入MAFLD评估与管理
  • 建议整体多学科管理以降低肝病负担并提高生活质量

核心结论

  • 国际专家建议将MAFLD考量纳入HCV消除工作,对获SVR者采取整体多学科管理以降低肝病负担并提高生活质量。

研究设计与样本

  • 本文为观点性综述,回顾HCV、代谢功能障碍与MAFLD相互作用的文献,由国际专家提出管理建议。

主要发现

  • HCV患病率下降被MAFLD患病率显著上升所抵消,后者可能持续驱动肝病进展并削弱DAA对终末期肝病和HCC的获益。

关键数值与推荐

  • WHO提出2030年全球消除HCV,具体目标为新发病毒性肝炎感染减少80%、相关死亡减少65%。

临床怎么用

  • 对DAA治疗后获SVR的HCV患者,应同时评估和管理MAFLD,采用整体多学科照护以降低发病和死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization (WHO) set a goal to eliminate hepatitis C (HCV) infection globally by 2030, with specific targets to reduce new viral hepatitis infections by 80% and reduce related deaths by 65%. However, an overlooked aspect that may hinder these efforts is the impact other liver diseases could have by continuing to drive liver disease progression and offset the beneficial impact of DAAs on end-stage liver disease and hepatocellular carcinoma (HCC). In particular, the decrease in HCV prevalence has been countered by a marked increase in the prevalence of metabolic-associated fatty liver disease (MAFLD). AIMS: To review the potential interaction of HCV and MAFLD. METHODS: We have reviewed the literature relating to an arrange of interaction of HCV, metabolic dysfunction and MAFLD. RESULTS: In this viewpoint, international experts suggest a holistic and multidisciplinary approach for the management of the growing number of treated HCV patients who achieved SVR, taking into consideration the overlooked impact of MAFLD for reducing morbidity and mortality in people who have had HCV. CONCLUSIONS: This will strengthen and improve the continuum of care cascade for patients with liver disease(s) and holds the potential to alleviate the cost burden of disease; and increase quality of life for patients following DAAs treatment.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fouad Y, Lazarus JV, Negro F, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021. PMID: 33751604. doi:10.1111/apt.16346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。